Wood, A., Rachel Denholm, Hollings, S., Cooper, J. A., Ip, S., Walker, V., … Consortium, C.-C.-U. (2021). Linking electronic health records for research on a nationwide cohort including over 54 million people in England. MedRxiv, 2021.02.22.21252185. Cite
Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., … Davies, N. M. (2021). Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Research, 6, 16. Cite
Levin, M. G., Zuber, V., Walker, V. M., Klarin, D., Lynch, J., Malik, R., … Program, on behalf of the V. M. V. (2021). Prioritizing the Role of Major Lipoproteins and Subfractions as Risk Factors for Peripheral Artery Disease. MedRxiv, 2021.01.11.21249148. Cite
Nounu, A., Walker, V., & Richmond, R. C. (2021). Letter regarding, "Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses." Journal of Cancer Research and Clinical Oncology. Cite
Hyman, M. C., Levin, M. G., Gill, D., Walker, V. M., Georgakis, M. K., Davies, N. M., … Damrauer, S. M. (2021). Genetically Predicted Blood Pressure and Risk of Atrial Fibrillation. Hypertension. https://doi.org/10.1161/HYPERTENSIONAHA.120.16191 Cite
Walker, V. M., Davies, N. M., Martin, R. M., & Kehoe, P. G. (2020). Comparison of Antihypertensive Drug Classes for Dementia Prevention. Epidemiology, 31, 852–859. Cite
Zheng, J., Haberland, V., Baird, D., Walker, V., Haycock, P. C., Hurle, M. R., … Gaunt, T. R. (2020). Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nature Genetics, 1–10. Cite
Zheng, J., Zhang, Y., Rasheed, H., Walker, V., Sugawara, Y., Li, J., … Gaunt, T. (2020). Trans-ethnic Mendelian randomization study reveals causal relationships between cardio-metabolic factors and chronic kidney disease. MedRxiv, 2020.09.04.20188284. Cite
Levin, M. G., Klarin, D., Walker, V. M., Gill, D., Lynch, J., Lee, K. M., … Program, V. M. V. (2020). Genetic Variation in Blood Pressure and Lifetime Risk of Peripheral Artery Disease: A Mendelian Randomization Study. MedRxiv, 2020.08.23.20180240. Cite
Walker, V. M., Kehoe, P. G., Martin, R. M., & Davies, N. M. (2020). Repurposing antihypertensive drugs for the prevention of Alzheimer's disease: a Mendelian randomization study. International Journal of Epidemiology, 49, 1132–1140. Cite
Yarmolinsky, J., Bull, C. J., Walker, V. M., Nounu, A., & Davey Smith, G. (2020). Mendelian randomization applied to pharmaceutical use: the case of metformin and lung cancer. International Journal of Epidemiology, 49, 1410–1411. Cite
Walker, V. M., Harrison, S., Carter, A. R., Gill, D., Tzoulaki, I., & Davies, N. M. (2020). The consequences of adjustment, correction and selection in genome-wide association studies used for two-sample Mendelian randomization. MedRxiv. Cite
Ponsford, M., Gkatzionis, A., Walker, V., Grant, A. J., Wootton, R. E., Moore, L. S. P., … Gill, D. (2020). Cardiometabolic Traits, Sepsis and Severe COVID-19: A Mendelian Randomization Investigation. Circulation. Cite
Walker, V. M., Davies, N. M., Hemani, G., Zheng, J., Haycock, P., Gaunt, T., … Martin, R. (2019). Using the MR-Base platform to investigate risk factors and drug targets for thousands of phenotypes. Wellcome Open Research. Cite
Gill, D., Walker, V. M., Martin, R. M., Davies, N. M., & Tzoulaki, I. (2019). Comparison with randomized controlled trials as a strategy for evaluating instruments in Mendelian randomization. International Journal of Epidemiology. Cite
Walker, V. M., Davey Smith, G., Davies, N. M., & Martin, R. M. (2017). Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. International Journal of Epidemiology, 46, 2078–2089. Cite
Walker, V. M., Davies, N. M., Windmeijer, F., Burgess, S., & Martin, R. M. (2017). Power calculator for instrumental variable analysis in pharmacoepidemiology. International Journal of Epidemiology, 46, 1627–1632. Cite